A detailed history of Black Rock Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Black Rock Inc. holds 18,440,729 shares of BCRX stock, worth $114 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,440,729
Previous 18,681,370 1.29%
Holding current value
$114 Million
Previous $112 Million 16.28%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$4.89 - $7.65 $1.18 Million - $1.84 Million
-240,641 Reduced 1.29%
18,440,729 $93.7 Million
Q4 2023

Feb 13, 2024

BUY
$4.98 - $6.77 $9.5 Million - $12.9 Million
1,907,066 Added 11.37%
18,681,370 $112 Million
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $8.58 Million - $10.1 Million
1,278,601 Added 8.25%
16,774,304 $119 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $4.67 Million - $5.91 Million
670,905 Added 4.53%
15,495,703 $109 Million
Q1 2023

May 12, 2023

SELL
$7.94 - $11.84 $747,606 - $1.11 Million
-94,157 Reduced 0.63%
14,824,798 $124 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $12 Million - $16.2 Million
1,143,960 Added 8.3%
14,918,955 $171 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $2.29 Million - $3.15 Million
-212,423 Reduced 1.52%
13,774,995 $174 Million
Q2 2022

Aug 12, 2022

SELL
$7.89 - $17.88 $903,854 - $2.05 Million
-114,557 Reduced 0.81%
13,987,418 $148 Million
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $7.92 Million - $13.5 Million
-685,420 Reduced 4.64%
14,101,975 $229 Million
Q4 2021

Feb 10, 2022

SELL
$11.18 - $15.46 $6.08 Million - $8.4 Million
-543,463 Reduced 3.54%
14,787,395 $205 Million
Q3 2021

Nov 09, 2021

SELL
$14.21 - $17.65 $2.14 Million - $2.66 Million
-150,469 Reduced 0.97%
15,330,858 $220 Million
Q2 2021

Aug 11, 2021

BUY
$9.5 - $17.24 $147 Million - $267 Million
15,481,327 New
15,481,327 $245 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.15B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.